Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTOv: Adaptive Carboplatin Therapy in Ovarian Cancer
NCT05080556Phase 2Recruiting
- Sponsor
- University College London
- Start
- May 2023
- Primary completion
- Nov 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by University College London. Started May 2023; status: recruiting.
02
Drugs
carboplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05080556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05080556.